Profile data is unavailable for this security.
About the company
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
- Revenue in USD (TTM)35.84m
- Net income in USD-251.23m
- Incorporated2013
- Employees246.00
- LocationEditas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
- Phone+1 (617) 401-9000
- Fax+1 (302) 655-5049
- Websitehttps://www.editasmedicine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | 23.00k | -176.44m | 177.89m | 227.00 | -- | 0.3787 | -- | 7,734.20 | -3.17 | -3.17 | 0.0004 | 10.14 | 0.00004 | -- | -- | 101.32 | -30.80 | -32.02 | -32.01 | -33.96 | -- | -- | -767,126.10 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -11.86m | 178.34m | 8.00 | -- | 45.31 | -- | -- | -0.1105 | -0.1105 | 0.00 | 0.0353 | 0.00 | -- | -- | 0.00 | -101.10 | -57.21 | -247.64 | -73.22 | -- | -- | -- | -- | -- | -16.59 | 0.0262 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
| Nuvectis Pharma Inc | 0.00 | -20.16m | 178.44m | 13.00 | -- | 8.52 | -- | -- | -1.12 | -1.12 | 0.00 | 0.8866 | 0.00 | -- | -- | 0.00 | -80.87 | -- | -115.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.65 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -79.88m | 187.05m | 56.00 | -- | 0.8224 | -- | -- | -1.65 | -1.65 | 0.00 | 4.45 | 0.00 | -- | -- | 0.00 | -29.57 | -- | -30.97 | -- | -- | -- | -- | -- | -- | -- | 0.094 | -- | -- | -- | 47.35 | -- | -- | -- |
| Omeros Corp | 0.00 | -176.34m | 187.50m | 202.00 | -- | -- | -- | -- | -3.04 | -2.64 | 0.00 | -3.68 | 0.00 | -- | -- | 0.00 | -52.43 | -50.90 | -66.50 | -63.20 | -- | -- | -- | -- | -- | -8.22 | 2.16 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| Editas Medicine Inc | 35.84m | -251.23m | 190.87m | 246.00 | -- | 3.06 | -- | 5.33 | -3.04 | -3.04 | 0.4338 | 0.7457 | 0.1018 | -- | 94.93 | 145,674.80 | -71.37 | -34.19 | -89.03 | -38.43 | -- | -- | -701.06 | -373.02 | -- | -- | 0.4665 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
| CARGO Therapeutics Inc | 0.00 | -216.19m | 193.22m | 167.00 | -- | 0.6841 | -- | -- | -4.62 | -4.62 | 0.00 | 6.13 | 0.00 | -- | -- | 0.00 | -55.12 | -- | -60.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -70.66 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -95.23m | 194.00m | 65.00 | -- | 1.34 | -- | -- | -1.49 | -1.49 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -45.52 | -45.05 | -49.68 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -27.13m | 194.57m | 15.00 | -- | 6.39 | -- | -- | -0.3911 | -0.3911 | 0.00 | 0.3054 | 0.00 | -- | -- | 0.00 | -91.36 | -125.08 | -142.54 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -190.63m | 195.23m | 113.00 | -- | 1.79 | -- | -- | -3.62 | -3.62 | 0.00 | 2.06 | 0.00 | -- | -- | 0.00 | -52.04 | -33.79 | -56.32 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| ProKidney Corp | 306.00k | -68.43m | 195.73m | 204.00 | -- | -- | -- | 639.64 | -0.6024 | -0.6024 | 0.0027 | -3.41 | 0.0008 | -- | 0.1674 | 1,500.00 | -41.81 | -- | -- | -- | -- | -- | -54,233.33 | -- | -- | -- | 0.0002 | -- | -- | -- | -72.51 | -- | -- | -- |
| Codexis Inc | 49.82m | -74.46m | 198.00m | 188.00 | -- | 3.99 | -- | 3.97 | -0.9885 | -0.9885 | 0.6508 | 0.5991 | 0.3578 | 6.71 | 3.86 | 264,973.40 | -53.48 | -21.95 | -65.18 | -26.20 | 71.56 | 76.67 | -149.47 | -49.88 | 3.64 | -- | 0.3703 | -- | -15.39 | -2.82 | 14.38 | -- | 2.91 | -- |
| TriSalus Life Sciences Inc | 32.14m | -30.30m | 201.30m | 110.00 | -- | -- | -- | 6.26 | -1.05 | -1.05 | 1.19 | -1.06 | 1.38 | 1.31 | 6.61 | 292,190.90 | -116.96 | -- | -267.11 | -- | 85.60 | -- | -84.63 | -- | 1.78 | -8.14 | -- | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| AC Immune SA | 35.42m | -65.19m | 201.82m | 133.00 | -- | 1.70 | -- | 5.70 | -0.6529 | -0.6529 | 0.3535 | 1.18 | 0.1496 | -- | 47.48 | 266,334.30 | -27.53 | -27.41 | -39.31 | -30.60 | -- | -- | -184.05 | -505.58 | -- | -129.20 | 0.0518 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| Design Therapeutics Inc | 0.00 | -56.20m | 202.66m | 56.00 | -- | 0.8892 | -- | -- | -0.9918 | -0.9918 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -21.77 | -18.88 | -22.44 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
Data as of Jun 30 2025. Currency figures normalised to Editas Medicine Inc's reporting currency: US Dollar USD
32.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 7.40m | 8.97% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 6.08m | 7.37% |
| Morgan Stanley & Co. LLCas of 31 Mar 2025 | 2.55m | 3.09% |
| Geode Capital Management LLCas of 31 Mar 2025 | 1.94m | 2.36% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 1.85m | 2.24% |
| UBS Asset Management Switzerland AGas of 31 Mar 2025 | 1.60m | 1.94% |
| Bank of America, NA (Private Banking)as of 31 Mar 2025 | 1.50m | 1.82% |
| Dimensional Fund Advisors LPas of 31 Mar 2025 | 1.45m | 1.75% |
| Two Sigma Investments LPas of 31 Mar 2025 | 1.25m | 1.51% |
| Two Sigma Advisers LPas of 31 Mar 2025 | 1.22m | 1.47% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
